Core Insights - Ardelyx, Inc. announced the recipients of the 2026 Derek Forfang Patient Advocate Award, recognizing individuals who have made significant contributions to advocating for chronic kidney disease patients [1][2] Group 1: Award Overview - The Derek Forfang Patient Advocate Award was established in 2025 to honor Derek Forfang, a patient advocate who passed away in 2023 due to chronic kidney disease [2] - The award recipients were selected by Ardelyx's Derek Forfang Patient Advisory Council based on their achievements in advocating for chronic kidney disease patients [2] Group 2: Recipients' Contributions - Edward Drake II founded The Youth Needing Organ & Tissue Transplants Foundation, helping thousands affected by kidney disease and advocating for patient-centered kidney care [4] - Markesha Grayson, a kidney donor, educates communities about kidney health and has testified in support of the Kidney Patient Act [5] - Timmy Nelson shares his transplant journey and has developed a national education program impacting over 1700 social workers since 2024 [6] - Pesh Patel founded A Kidney Life to educate those living with kidney disease and hosts a podcast to discuss treatment and policy [7] - Glenda Roberts is an activist for kidney research, serving on multiple advisory committees and contributing to over 50 publications [8][9] Group 3: Company Background - Ardelyx is a commercial-stage biopharmaceutical company focused on developing innovative medicines for unmet medical needs, with two approved products in the U.S. [10] - The company's pipeline includes Phase 3 development of tenapanor for chronic idiopathic constipation and RDX10531, a next-generation NHE3 inhibitor [10] - Ardelyx has international agreements for the commercialization of tenapanor, including partnerships in Japan and China [10]

Core Insights - Ardelyx, Inc. announced positive results from a post hoc analysis of its IBS-C clinical development program, indicating that Tenapanor (IBSRELA) provides earlier and sustained symptom relief for patients with irritable bowel syndrome with constipation [1][2][4] Group 1: Clinical Findings - The post-hoc analysis pooled data from three clinical trials, showing that patients taking Tenapanor experienced improvements in bowel movement frequency as early as two weeks and significant relief from abdominal symptoms within 4-5 weeks [2] - Continued therapy for 12 weeks increased the likelihood of reporting meaningful symptom improvement across multiple symptoms, emphasizing the importance of sustained treatment [3] Group 2: Practical Implications - The analysis offers week-by-week insights into the timing and durability of Tenapanor's effects, aiding healthcare providers in setting realistic expectations for patients [4] - The sustained response, defined as improvement maintained over consecutive weeks, was observed in some patients, indicating that ongoing therapy is beneficial for achieving symptom relief [4] Group 3: Safety and Tolerability - No new or unexpected safety findings were reported, with Tenapanor generally well tolerated; the most common adverse event was mild-to-moderate diarrhea [4] - In clinical trials, diarrhea occurred in 16% of Tenapanor-treated patients compared to 4% in the placebo group, with severe diarrhea reported in 2.5% of patients [10][9] Group 4: Product Information - IBSRELA (Tenapanor) is a first-in-class retainagogue approved by the FDA for treating IBS-C in adults, acting as a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3) [1][6] - The drug works by reducing sodium absorption in the intestines, which helps retain water content and improves stool consistency while also reducing abdominal pain [6] Group 5: Company Overview - Ardelyx is a biopharmaceutical company focused on developing innovative medicines for unmet medical needs, with two commercial products approved in the U.S., including IBSRELA [12] - The company's pipeline includes ongoing Phase 3 development of Tenapanor for chronic idiopathic constipation and a next-generation NHE3 inhibitor [12]

Core Viewpoint - Ardelyx Inc. reported a breakeven performance for Q4 2025, with sales of $125.22 million, surpassing the consensus estimate of $118.13 million [1] Revenue Performance - IBSRELA (tenapanor) revenue grew 73% in 2025 to $274.2 million, contributing to total revenues of $407.3 million; Q4 revenue for IBSRELA was $86.6 million, up 61% year over year [2] - XPHOZAH (tenapanor) revenue in 2025 was $103.6 million, with Q4 revenue of $27.8 million; expected 2026 revenue for XPHOZAH is projected between $110 million and $120 million [4] Growth Expectations - Ardelyx anticipates full-year 2026 revenue for IBSRELA to be between $410 million and $430 million, indicating at least 50% growth compared to 2025 [2] - The company expects IBSRELA to achieve $1 billion in annual revenue by 2029, with further growth anticipated thereafter [3] Pipeline Developments - Ardelyx plans to submit a Supplemental New Drug Application to the FDA for the CIC indication, pending Phase 3 trial outcomes; enrollment in the ACCEL trial is expected to complete by the end of 2026 [5] - A development program for RDX10531, a next-generation sodium/hydrogen exchanger 3 (NHE3) inhibitor, is underway, with an Investigational New Drug submission planned for the second half of 2026 [6] Technical Analysis - Ardelyx shares are currently trading 17.6% below the 20-day simple moving average (SMA) and just 0.1% below the 100-day SMA, indicating short-term weakness [7] - The stock has increased 17.83% over the past 12 months and is closer to its 52-week highs than lows [7] Analyst Consensus - The stock carries a Buy Rating with an average price target of $12.86; recent analyst actions include maintaining a Buy rating with a target of $17.00 and raising the target to $19.00 [10]

Core Insights - Ardelyx, Inc. reported a significant revenue growth of 73% for IBSRELA in 2025, reaching $274.2 million, contributing to total revenues of $407.3 million for the year [1][3][10] - The company is focused on expanding its product offerings and has launched development programs for new indications and next-generation therapies [1][7][8] - Ardelyx anticipates continued growth in 2026, with projected IBSRELA revenues between $410 million and $430 million, indicating at least 50% growth compared to 2025 [4][6] Financial Performance - Total revenue for 2025 was $407.3 million, up from $333.6 million in 2024, driven primarily by IBSRELA's performance [10][14] - IBSRELA revenue for 2025 was $274.2 million, a 73% increase from $158.3 million in 2024, while XPHOZAH revenue was $103.6 million, down from $160.9 million in 2024 [3][14] - The company reported a net loss of $61.6 million for 2025, compared to a net loss of $39.1 million in 2024, with significant expenses related to commercialization and R&D [10][14][28] Product Development and Pipeline - Ardelyx is advancing its pipeline, including a Phase 3 trial for IBSRELA in chronic idiopathic constipation (CIC), with enrollment expected to complete by the end of 2026 [7][8] - The company has initiated a development program for RDX10531, a next-generation NHE3 inhibitor, with plans for an Investigational New Drug submission in the second half of 2026 [8][24] - The long-term strategy focuses on delivering novel therapies to patients with unmet medical needs and generating sustained shareholder value [2][22] Market Outlook - Ardelyx expects IBSRELA to achieve $1 billion in annual revenue by 2029, supported by increased prescribing depth and patient engagement [4][6] - The company aims to enhance its market presence through strategic initiatives and broaden its portfolio of innovative medicines [2][4]

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor) [3] - Ardelyx's pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas [3] Upcoming Conference Call - Ardelyx will hold a conference call on February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update for the full year and fourth quarter of 2025 [1] - The call will feature commentary from key members of the Ardelyx Executive Leadership Team, including the President and CEO, CFO, Chief Commercial Officer, and Chief Patient Officer [1] Commercialization Agreements - Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S., including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] - Knight Therapeutics is responsible for commercializing IBSRELA in Canada [3]

Core Insights - Ardelyx, Inc. has been granted a new patent for IBSRELA and XPHOZAH, which will expire on November 26, 2042, covering the formulation of tenapanor [1][2] Company Overview - Ardelyx is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [1][15] - The company has two commercial products approved in the U.S.: IBSRELA and XPHOZAH [15] Product Information IBSRELA (tenapanor) - IBSRELA is an oral formulation that acts as a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), reducing sodium absorption and retaining luminal water content, which helps in softening stool consistency [3][11] - It has been shown to alleviate abdominal pain by decreasing visceral hypersensitivity and intestinal permeability in animal models [3] XPHOZAH (tenapanor) - XPHOZAH is a phosphate absorption inhibitor that works locally in the gut to reduce phosphate absorption through the paracellular pathway [4][14] - It is administered as a single tablet taken twice daily, with diarrhea being the most common side effect reported in clinical trials [4][13] Patent and Intellectual Property - The newly granted patent reflects a Patent Term Adjustment due to delays from the USPTO, extending protections for Ardelyx's portfolio of medicines [2] - The patent will be submitted for listing in the FDA's Orange Book for both IBSRELA and XPHOZAH [1]

Core Insights - Ardelyx, Inc. has initiated the dosing of the first patient in the Phase 3 clinical trial ACCEL for IBSRELA (tenapanor), targeting chronic idiopathic constipation (CIC) in adults [1][2][3] Group 1: Clinical Trial Details - ACCEL is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of tenapanor for CIC, with an enrollment target of approximately 700 patients [2] - The trial will administer tenapanor twice daily for 26 weeks, with primary endpoints focusing on patient-reported outcomes related to constipation [2] - Enrollment is expected to continue throughout 2026, with topline data anticipated in the second half of 2027 [2] Group 2: Company Mission and Progress - Ardelyx aims to discover and commercialize innovative medicines that address significant unmet medical needs, with IBSRELA being a key product in their portfolio [1][11] - The Phase 3 trial represents a strategic move to expand the patient population benefiting from IBSRELA, which has already shown safety and efficacy in treating irritable bowel syndrome with constipation [3][11] Group 3: Market Context - Chronic idiopathic constipation affects over 34 million Americans, significantly impacting quality of life and healthcare costs [4][11] - The global prevalence of CIC is estimated to be between 10-17% of the population, indicating a substantial market opportunity for effective treatments [4][13]

Core Insights - Ardelyx, Inc. reported Q3 2025 product revenue of $105.5 million, reflecting a 15% year-over-year growth, driven primarily by strong performance from IBSRELA and XPHOZAH [1][2][13] - IBSRELA revenue reached $78.2 million in Q3 2025, marking a 92% increase year-over-year and a 20% increase compared to Q2 2025, with full-year 2025 revenue guidance raised to between $270-275 million [1][4][13] - XPHOZAH generated $27.4 million in revenue during Q3 2025, up 9% from Q2 2025, supported by increased demand and effective commercial strategies [1][5][13] - The company announced the development of RDX10531, a next-generation NHE3 inhibitor, which is expected to have applications across multiple therapeutic areas [1][6][21] Financial Performance - Total revenue for Q3 2025 was $110.3 million, compared to $98.2 million in Q3 2024, primarily due to increased IBSRELA revenue, despite a decline in XPHOZAH revenue [13][28] - Research and development expenses for Q3 2025 were $18.1 million, up from $15.3 million in Q3 2024, while selling, general and administrative expenses increased to $83.6 million from $65.0 million [13][28] - The net loss for Q3 2025 was $1.0 million, or $(0.00) per share, compared to a net loss of $0.8 million, or $(0.00) per share, in Q3 2024 [13][28] Corporate Developments - Ardelyx appointed Sue Hohenleitner as Chief Financial Officer, effective November 4, 2025, and announced other key appointments in August 2025 [7] - The company had a significant presence at the 2025 Annual Scientific Meeting for the American College of Gastroenterology, showcasing its commitment to advancing medical knowledge and product visibility [8]

Core Insights - Ardelyx, Inc. announced upcoming data presentations for XPHOZAH (tenapanor) at the American Society of Nephrology's Kidney Week, scheduled for November 5-9, 2025, in Houston [1][3] Company Overview - Ardelyx is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [1][12] - The company has two commercial products approved in the U.S.: IBSRELA (tenapanor) and XPHOZAH (tenapanor) [12] Product Information - XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. FDA to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis [2][11] - It is indicated as an add-on therapy for patients who have an inadequate response to phosphate binders or are intolerant to any dose of phosphate binder therapy [11] - XPHOZAH operates through a unique mechanism that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily [2][6] Upcoming Presentations - Ardelyx will present several posters at ASN's Kidney Week, including: - "Real-World Effectiveness of Tenapanor (XPHOZAH) for Treatment of Hyperphosphatemia in United States Patients on Dialysis" on November 6, 2025 [4] - "Treatment Satisfaction with Tenapanor (XPHOZAH): Real-World Survey of Patients with End-Stage Renal Disease and Hyperphosphatemia" on November 6, 2025 [4] - "Tenapanor Improves Bowel Movements in Patients with End-Stage Kidney Disease and Mild to Severe Constipation" on November 6, 2025 [5] Industry Context - Hyperphosphatemia is a serious condition affecting the majority of the 550,000 patients in the U.S. with CKD on maintenance dialysis [7][8] - The kidneys are responsible for eliminating excess phosphate, and as kidney function declines, phosphate is not adequately removed from the body, leading to hyperphosphatemia [8]

Core Points - Ardelyx, Inc. will hold a conference call on October 30, 2025, at 4:30 p.m. Eastern Time to discuss third-quarter financial results and provide a business update [1] - The conference call will be accessible via phone and will also be webcasted live on the company's website, with a replay available for 30 days [2] Company Overview - Ardelyx is focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the U.S.: IBSRELA (tenapanor) and XPHOZAH (tenapanor) [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3]